MyoKardia Accelerates Timing for Mavacamten Topline Phase 3 Data
18 July 2019 - 11:29PM
Dow Jones News
By Michael Dabaie
MyoKardia Inc. (MYOK) now anticipates reporting topline data
from the EXPLORER-HCM trial in the second quarter of 2020, ahead of
previous guidance of the second half of 2020.
Patient screening has closed for the Phase 3 EXPLORER-HCM study
to assess mavacamten in treating patients with obstructive
hypertrophic cardiomyopathy. Enrollment into the pivotal trial is
expected to be completed by mid-August, MyoKardia said.
MyoKardia also said it re-acquired U.S. royalty rights to
mavacamten and MYK-224 from Sanofi S.A. (SNY, SAN.FR). As
consideration for the buyback of the U.S. royalty rights to these
programs, MyoKardia is paying Sanofi $50 million upfront, with an
additional $30 million payable by June 30, 2020.
MyoKardia shares were up 0.4% premarket to $50.00.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 18, 2019 09:14 ET (13:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (EU:SAN)
Historical Stock Chart
From May 2023 to May 2024